Navigation Links
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Date:6/3/2008

4 or more cycles (4 week cycle)

Antitumor activity and toxicity were similar between the Injection and Injectable Suspension products.

-- Of the 31 patients enrolled, 21 were treated with Kosan's Injection

product (Cremophor(R)-containing formulation and 10 were treated with

Kosan's Injectable Suspension product (contains no Cremophor). In

addition, 4 of the patients treated initially with the Injection

formulation crossed over to receive the Injectable Suspension

formulation.

-- For the Injection product: 18 were evaluable and 11 responded

(4 PR, 4 tumor regressions, 3 SD), yielding a PR response rate of

22% and a clinical benefit incidence of 61%.

-- For the Injectable Suspension product: 9 were evaluable and 6

responded (3 PR, 1 tumor regression, 2 SD), yielding a PR response

rate of 33% and a clinical benefit incidence of 67%.

-- Patients with an objective response on the Injection product

maintained their objective response after crossover to the

Injectable Suspension product.

Tanespimycin plus trastuzumab was highly tolerable at the recommended Phase 2 dose of 450 mg/m2 weekly. Common toxicities were mainly mild-to-moderate diarrhea, fatigue, nausea, headache and vomiting (limited duration and amenable to supportive care). The few drug-related Grade 3 and 4 toxicities (including fatigue, increased AST and headache, two patients each) were manageable and only one patient discontinued treatment for an adverse event. Noticeably absent were toxicities common to cytotoxic chemotherapy including alopecia and myelosuppression. The Injectable Suspension product provided considerable advantages over the Injection product, including shorter time of infusion, no need for steroid or antihistamine premedications and ease of pharmacist preparation.

Kosan anticipates conducti
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
4. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
10. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
11. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 ... report is available in its catalogue: ... 2014-2024 http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html ... – discover technological and commercial prospects What ... delivery market? Visiongain,s brand new report shows ...
(Date:8/28/2014)... Pharmatech initiated enrollment for its AccessPPM ... method for matching cancer patients to cancer clinical ... specific cancers, disease staging, and genetic mutations - ... in the first place. The challenge that the ... be well known to the patient or even ...
(Date:8/28/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today updates the timeline for the GMP ... The Company is scheduled to submit ... Food & Drug Administration,s (CFDA) review in the ...
Breaking Medicine Technology:Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... The High Court of Germany ( Bundesgerichtshof ) handed ... in its dispute with the Finnish company Medix Biochemica. The ... associated with Medix,s ActimPROM test is null and void due ... to pay AmniSure® an undisclosed amount to be determined by ...
... -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX ... products and services in the People,s Republic of China, ... results for the three and nine-month periods ended December ... market closes. Management will host a conference call at ...
Cached Medicine Technology:German High Court Rules in Favor of AmniSure® as New European Guidelines Published 2Chindex International to Report Financial Results for the Three and Nine-Month Periods Ended December 31, 2010 2
(Date:8/29/2014)... Food and Drug Administration (FDA)-approved treatment for decreasing ... effective at reducing fracture risk as other current ... loss. With the use of wide- and small-angle ... out experiments at the U.S. Department of Energy,s ... Laboratory that revealed an additional mechanism underlying raloxifene ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
(Date:8/29/2014)... 2014 The 8th Annual Paint Columbus Pink® ... a Cause, Pink Pooch Contest, Light of Life Ceremony, Power ... Pink Bow Campaign – all in support of cancer awareness. ... this year…. Paint Columbus Pink Foam and Obstacle Challenge on ... 727 54th Street, Columbus, Georgia 31904. It will be the ...
(Date:8/29/2014)... 29, 2014 After having a double ... had to have breast reconstruction. She found that the ... she decided that there needed to be a solution. ... a woman or man who needs or wants breast ... promotes confidence and peace of mind. Producible in design ...
(Date:8/29/2014)... 2014 University of Western States (UWS), ... announced that Daniel Redwood, DC, director of the human ... the Year,” by the Missouri State Chiropractors Association (MSCA) ... , Patrick Montgomery, DC, president of the MSCA, cited ... Missouri House Task Force for Medicaid Reform, in bringing ...
Breaking Medicine News(10 mins):Health News:Revealing a novel mode of action for an osteoporosis drug 2Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Paint Columbus Pink Cancer Awareness/Kick-Off Meeting for Anyone Interested in Participating 2Health News:University of Western States Director of Human Nutrition and Functional Medicine Daniel Redwood, DC, named Missouri Educator of the Year by MSCA 2
... June 03, 2010 The John Theurer Cancer Center ... physicians and researchers will present 16 abstracts on treatment ... during the Annual Meeting of American Society of Clinical ... "At the John Theurer Cancer Center, we,re ...
... Americans now have choices ... treatment in the USA, Medical Tourism is the answer. , ... Carlsbad, CA (PRWEB) June 2, 2010 – Website promotes the healthcare options ... USA. , , ,Global Medical Connect is a one stop medical tourism shop to take care ...
... , THURSDAY, June 3 (HealthDay News) -- Fatal medication ... of the inexperience of new medical residents, a new ... July, and those first weeks may be a dangerous ... the University of California, San Diego. , The ...
... say it,s not always that simple, , THURSDAY, June 3 ... in many a parent. But having to incorporate information ... make an already sensitive subject even more complicated. , Yet ... As assisted reproduction technology, in which someone other than the ...
... ... Lake Host Malaria Awareness Soccer Clinic this Thursday for Local Youth as part of White ... ... the United Nations Foundation ’s Nothing But Nets campaign are teaming up to raise ...
... ... research study that provides detailed analyses on health plans’ coverage and management of ... ... Pharmaceuticals Service is an ongoing market research study that provides detailed analyses on ...
Cached Medicine News:Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 3Health News:Global Medical Connect Launches New Website for the Growing Medical Tourism Industry 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 2Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 3Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 2Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 3
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
... MicroDigital IP 6.2 Series Image Processing Video ... for all surgical specialties. This camera incorporates ... such as brightness, enhancement, gain, and white ... Multiple-range image enhancement and adjustable picture level ...
... Halogen Light Source is similar ... addition of dual lamps and ... light source is ideal for ... the added feature of a ...
Medicine Products: